Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10+ advanced non-small cell lung cancer

Cellular therapy for the treatment of solid tumors

(2021) Joseph M. Grimes et al.   TRANSFUSION AND APHERESIS SCIENCE

T-Cell Therapy for Lymphoma Using Nonengineered Multiantigen-Targeted T Cells Is Safe and Produces Durable Clinical Effects

(2021) Spyridoula Vasileiou et al.   JOURNAL OF CLINICAL ONCOLOGY

TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers

(2021) Nisha B. Nagarsheth et al.   NATURE MEDICINE

The Emerging Landscape of Immune Cell Therapies

(2020) Evan W. Weber et al.   CELL

Phase I dose escalation and expansion trial to assess the safety and efficacy of ADP-A2M4 SPEAR T cells in advanced solid tumors.

(2020) David S. Hong et al.   JOURNAL OF CLINICAL ONCOLOGY

976TiP SPEARHEAD-2 trial design: A phase II pilot trial of ADP-A2M4 in combination with pembrolizumab in patients with recurrent or metastatic head and neck cancer

(2020) E.E. Cohen et al.   ANNALS OF ONCOLOGY

Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2

(2019) Linh T. Nguyen et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

1670OADP-A2M4 (MAGE-A4) in patients with synovial sarcoma

(2019) B A Van Tine et al.   ANNALS OF ONCOLOGY

Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma

(2019) Indu Ramachandran et al.   Journal for ImmunoTherapy of Cancer

T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma

(2018) Karolina Woroniecka et al.   CLINICAL CANCER RESEARCH

Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 c259 T Cells in Synovial Sarcoma

(2018) Sandra P. D'Angelo et al.   Cancer Discovery

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2018) Freddie Bray et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Affinity-enhanced T-cell receptors for adoptive T-cell therapy targeting MAGE-A10: strategy for selection of an optimal candidate

(2018) Ellen C. Border et al.   OncoImmunology

Adoptive transfer of tumor-infiltrating lymphocytes in melanoma: a viable treatment option

(2018) Maartje W. Rohaan et al.   Journal for ImmunoTherapy of Cancer

Prospects for gene-engineered T cell immunotherapy for solid cancers

(2016) Christopher A Klebanoff et al.   NATURE MEDICINE

Current concepts in the diagnosis and management of cytokine release syndrome

(2014) D. W. Lee et al.   BLOOD

Adoptive Transfer of MART-1 T-Cell Receptor Transgenic Lymphocytes and Dendritic Cell Vaccination in Patients with Metastatic Melanoma

(2014) T. Chodon et al.   CLINICAL CANCER RESEARCH

A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1-Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response

(2014) P. F. Robbins et al.   CLINICAL CANCER RESEARCH

Expression and Immune Responses to MAGE Antigens Predict Survival in Epithelial Ovarian Cancer

(2014) Sayeema Daudi et al.   PLoS One

Adoptive T Cell Transfer for Cancer Immunotherapy in the Era of Synthetic Biology

(2013) Michael Kalos et al.   IMMUNITY

MAGE-A10 cancer/testis antigen is highly expressed in high-grade non-muscle-invasive bladder carcinomas

(2012) Chantal Mengus et al.   INTERNATIONAL JOURNAL OF CANCER

MAGE-A10 is a nuclear protein frequently expressed in high percentages of tumor cells in lung, skin and urothelial malignancies

(2010) Elke Schultz-Thater et al.   INTERNATIONAL JOURNAL OF CANCER

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER